左卡尼汀联合黄芪注射液治疗急性病毒性心肌炎的疗效观察

Efficacy of levocarnitine combined with astragalus injection in treatment ofacute viral myocarditis

目的观察左卡尼汀联合黄芪注射液治疗急性病毒性心肌炎(AVM)的临床疗效和安全性。方法将106例AVM患者按照随机数字表分为观察组和对照组,每组各53例,对照组在常规治疗基础上加用左卡尼汀,观察组则在对照组的基础上加用黄芪注射液治疗,并比较两组的临床疗效。结果观察组总有效率为96.23%,明显高于对照组的81.13%,两组相比较差异有统计学意义(P<0.05),两组治疗后的CK-MB、LDH、AST、cTnI与治疗前比较,均差异有统计学意义(P<0.05),观察组治疗后的CK-MB、LDH、AST、cTnI与对照组相比差异有显著性意义(P<0.05、P<0.01)。观察组治疗后的心功能明显优于对照组(P<0.05)。结论左卡尼汀联合黄芪注射液治疗AVM患者疗效确切,改善心电图变化与心肌酶谱,副作用小。

Objective To observe clinicalefficacy and safety of the levocarnitine combined with astragalus injection in treatment ofacute viral myocarditis. Methods 106 cases of AVMpatientsweredivided intoobservation groupandthecontrol group, accordingtotherandom number table. 53 cases for each group, the control group were treated by the levocarnitine onthebasis of conventional therapy, and the observation group was treated by astragalus injection onthe basisoftheeontrol group. And then the clinical efficacies of the two groups were compared. Results The total effeetiverate ofthe observation group was 96.23%, was significantly higher than the control group with 81.13%, thedifference was statistically significant（ P 〈 0. 05 ）. After treatment, CK- MB, LDH, AST, eTnleompared with before treatment, differences were statistically significant（ P 〈 0. 05 ）. The observation groupafter treatment, CK-MB, LDH, AST, cTnI difference eomparedwith the eontrolgroupwas significant（P 〈 0. 05, P 〈 0. 01 ）. The observation groupafter treatment, heart functionwassignifieantlybetter than the controlgroup （P 〈 0. 05 ）. Conclusions The levocarnitine combined with astragalus injection in treatment ofacute viral myocarditis has efficacyto impro,eECG changesandmyocardial enzymes, has little side effect.